Consider writing about:
An agreement by a North Carolina-based drug manufacturer to pay more than $46 million to resolve kickback allegations; what stands out to you about the Veloxis Pharmaceuticals case and the resulting deferred prosecution agrement; what pharmaceutical companies should know about their obligations under the Open Payments Program (aka the Physician Payments Sunshine Act) and related enforcement trends and liability risks, whether specifically involving the Sunshine Act or, more broadly speaking, involving the False Claims Act, alleged healthcare fraud, and whistleblower activity; how companies may be able to minimize legal fallout after the fact in cases of this type.
Related information: